Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies

Molecules. 2010 Oct 12;15(10):7035-74. doi: 10.3390/molecules15107035.


Despite considerable improvements in the tolerance and efficacy of novel chemotherapeutic agents, the mortality of hematological malignancies is still high due to therapy relapse, which is associated with bad prognosis. Dietary polyphenolic compounds are of growing interest as an alternative approach, especially in cancer treatment, as they have been proven to be safe and display strong antioxidant properties. Here, we provide evidence that both resveratrol and curcumin possess huge potential for application as both chemopreventive agents and anticancer drugs and might represent promising candidates for future treatment of leukemia. Both polyphenols are currently being tested in clinical trials. We describe the underlying mechanisms, but also focus on possible limitations and how they might be overcome in future clinical use--either by chemically synthesized derivatives or special formulations that improve bioavailability and pharmacokinetics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antioxidants* / administration & dosage
  • Antioxidants* / chemistry
  • Antioxidants* / therapeutic use
  • Apoptosis
  • Cell Cycle
  • Cell Proliferation
  • Clinical Trials as Topic
  • Curcumin* / administration & dosage
  • Curcumin* / chemistry
  • Curcumin* / therapeutic use
  • Diet*
  • Hematologic Neoplasms / drug therapy*
  • Humans
  • Molecular Structure
  • Neoplasms / drug therapy
  • Oxidative Stress
  • Reactive Oxygen Species / metabolism
  • Resveratrol
  • Stilbenes* / administration & dosage
  • Stilbenes* / chemistry
  • Stilbenes* / therapeutic use


  • Antioxidants
  • Reactive Oxygen Species
  • Stilbenes
  • Curcumin
  • Resveratrol